Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial-MedSci.cn

Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial

Denda, T; Takashima, A; Gamoh, M; Iwanaga, I; Komatsu, Y; Takahashi, M; Nakamura, M; Ohori, H; Sakashita, A; Tsuda, M; Kobayashi, Y; Baba, H; Kotake, M; Ishioka, C; Yamada, Y; Sato, A; Yuki, S; Morita, S; Takahashi, S; Yamaguchi, T; Shimada, K

Yamaguchi, T (corresponding author), Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Surg, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138677, Japan.

Abstract

Aim: The TRICOLORE trial previously demonstrated that S-1 and irinotecan plus bevacizumab was non-inferior, based on progression-free survival (PFS), ......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial

科室

工具

服务